Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including β-lactamase-producing and vancomycin-resistant isolates

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 6, 2007, Pages 2043-2047

  Arias, Cesar A ^a,b   Singh, Kavindra V ^a   Panesso, Diana ^b   Murray, Barbara E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSIDAD EL BOSQUE   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAMASE; CEFTOBIPROLE; GENTAMICIN; STREPTOMYCIN; VANCOMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEPHALOSPORINS; DRUG SYNERGISM; ENTEROCOCCUS FAECALIS; GENTAMICINS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; STREPTOMYCIN; VANCOMYCIN RESISTANCE;

EID: 34250172067     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00131-07     Document Type: Article

References (24)

1. Bogdanovich, T., C. Clark, L. Ednie, G. Lin, K. Smith, S. Shapiro, and P. C. Appelbaum. 2006. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob. Agents Chemother. 50:2050-2057.
2. Chambers, H. F. 2005. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49:884-888.
3. Clinical and Laboratory Standards Institute. 2005. Performance standard for antimicrobial susceptibility testing; 15th informational supplement M100-S15. Clinical and Laboratory Standards Institute, Wayne, Pa.
4. Coque, T. M., and B. E. Murray. 1995. Identification of Enterococcus faecalis strains by DNA hybridization and pulsed-field gel electrophoresis. J. Clin. Microbiol. 33:3368-3369.
5. Davies, T. A., W. Shang, and K. Bush. 2006. Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob. Agents Chemother. 50:2530-2532.
6. Deshpande, L. M., and R. N. Jones. 2003. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin. Microbiol. Infect. 9:1120-1124.
7. Entenza, J. M., P. Hohl, I. Heinze-Krauss, M. P. Glauser, and P. Moreillon. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177.
8. Fontana, R., M. Ligozzi, F. Pittaluga, and G. Satta. 1996. Intrinsic penicillin resistance in enterococci. Microb. Drug Resist. 2:209-213.
9. Goldstein, E. J., D. M. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrrell, and H. T. Fernandez. 2006. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob. Agents Chemother. 50:3959-3962.
10. Gonzales, R. D., P. C. Schreckenberger, M. B. Graham, S. Kelkar, K. DenBesten, and J. P. Quinn. 2001. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357:1179.
11. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-536.
12. Jacob, A. E., and S. J. Hobbs. 1974. Conjugal transfer of plasmid-borne multiple antibiotic resistance in Streptococcus faecalis var. zymogenes. J. Bacteriol. 117:360-372.
13. Ligozzi, M., F. Pittaluga, and R. Fontana. 1996. Modification of penicillin-binding protein 5 associated with high-level ampicillin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 40:354-357.
14. Moellering, R. C., Jr., C. Wennersten, and A. N. Weinberg. 1971. Synergy of penicillin and gentamicin against enterococci. J. Infect. Dis. 124(Suppl.):S207-S209.
15. Murray, B. E., and B. Mederski-Samaroj. 1983. Transferable beta-lactamase: a new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J. Clin. Investig. 72:1168-1171.
16. Murray, B. E., K. V. Singh, R. P. Ross, J. D. Heath, G. M. Dunny, and G. M. Weinstock. 1993. Generation of restriction map of Enterococcus faecalis OG1 and investigation of growth requirements and regions encoding biosynthetic function. J. Bacteriol. 175:5216-5223.
17. Nallapareddy, S. R., H. Wenxiang, G. M. Weinstock, and B. E. Murray. 2005. Molecular characterization of a widespread, pathogenic, and antibiotic resistance-receptive Enterococcus faecalis lineage and dissemination of its putative pathogenicity island. J. Bacteriol. 187:5709-5718.
18. Robredo, B., K. V. Singh, F. Baquero, B. E. Murray, and C. Torres. 2000. Vancomycin-resistant enterococci isolated from animals and food. Int. J. Food Microbiol. 54:197-204.
19. Rouse, M. S., M. M. Hein, P. Anguita-Alonso, J. M. Steckelberg, and R. Patel. 2006. Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. Diagn. Microbiol. Infect. Dis. 55:333-336.
20. Rybkine, T., J. L. Mainardi, W. Sougakoff, E. Collatz, and L. Gutmann. 1998. Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance. J. Infect. Dis. 178:159-163.
21. Schmitt-Hoffmann, A., L. Nyman, B. Roos, M. Schleimer, J. Sauer, N. Nashed, T. Brown, A. Man, and E. Weidekamm. 2004. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48:2576-2580.
22. Schmitt-Hoffmann, A., B. Roos, M. Schleimer, J. Sauer, A. Man, N. Nashed, T. Brown, A. Perez, E. Weidekamm, and P. Kovacs. 2004. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48:2570-2575.
23. Wootton, M., K. E. Bowker, H. A. Holt, and A. P. MacGowan. 2002. BAL9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials. J. Antimicrob. Chemother. 49:535-539.
24. Zorzi, W., X. Y. Zhou, O. Dardenne, J. Lamotte, D. Raze, J. Pierre, L. Gutmann, and J. Coyette. 1996. Structure of the low-affinity penicillin-binding protein 5 PBP5fm in wild-type and highly penicillin-resistant strains of Enterococcus faecium. J. Bacteriol. 178:4948-4957.